APA (7th ed.) Citation

F, G., A, R., F, M., G, R., A, P., M, G., . . . F, P. (2023). Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin. Clinical colorectal cancer, 22(4), 450. https://doi.org/10.1016/j.clcc.2023.08.005

Chicago Style (17th ed.) Citation

F, Ghelardi, et al. "Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin." Clinical Colorectal Cancer 22, no. 4 (2023): 450. https://doi.org/10.1016/j.clcc.2023.08.005.

MLA (9th ed.) Citation

F, Ghelardi, et al. "Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin." Clinical Colorectal Cancer, vol. 22, no. 4, 2023, p. 450, https://doi.org/10.1016/j.clcc.2023.08.005.